LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Search

Mirati Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

0

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-0.05% downside

Nachrichtenstimmung

By Acuity

100%

0%

320 / 344 Ranking in Healthcare

Mirati Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juni 2026, 19:20 UTC

Wichtige Markttreiber

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5. Juni 2026, 21:27 UTC

Ergebnisse

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. Juni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. Juni 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. Juni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. Juni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. Juni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. Juni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. Juni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. Juni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. Juni 2026, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. Juni 2026, 17:50 UTC

Ergebnisse

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. Juni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. Juni 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. Juni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5. Juni 2026, 15:25 UTC

Ergebnisse

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5. Juni 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5. Juni 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5. Juni 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5. Juni 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer-Vergleich

Kursveränderung

Mirati Therapeutics Inc Prognose

Kursziel

By TipRanks

-0.05% Nachteil

12-Monats-Prognose

Durchschnitt 58.67 USD  -0.05%

Hoch 59 USD

Tief 58 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Mirati Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

0

Buy

5

Halten

0

Sell

Stimmung

By Acuity

320 / 344 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat